Clinical trials · Texas
Myelodysplastic Syndromes clinical trials in Texas
We’re tracking 68 recruiting myelodysplastic syndromes studies with a site in Texas — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Texas
- NCT05308264RecruitingPhase 1/Phase 2
R289 for lower-risk MDS that still needs blood support
This Phase 1/2 study tests R289 in adults with lower-risk myelodysplastic syndromes (MDS) whose disease keeps causing anemia and/or ongoing need for red blood cell transfusions. It may help reduce blood problems and treat MDS when standard options haven’t worked well enough or aren’t suitable.
Dallas, TexasAges 18 years+ - NCT06641414RecruitingPhase 3
Lisaftoclax and azacytidine for higher-risk MDS
This trial tests a new drug, lisaftoclax, combined with azacytidine for people newly diagnosed with higher-risk myelodysplastic syndrome (MDS). The goal is to see if this combination can help control the disease better.
Houston, TexasAges 18 years+ - NCT06499285RecruitingPhase 3
Study of elritercept for anemia in low-risk MDS needing transfusions
This trial tests an investigational drug called elritercept for adults with a specific type of low-risk MDS (myelodysplastic syndromes) who have anemia (low red blood cells) and need regular blood transfusions. The goal is to see if elritercept can reduce or eliminate the need for transfusions.
Denison, TexasAges 18 years+ - NCT07422480RecruitingPhase 3
Comparing elritercept to epoetin alfa for anemia in MDS needing transfusions
This trial tests a new drug called elritercept against a standard treatment, epoetin alfa, for people with a low-risk form of MDS who need regular blood transfusions for anemia. The goal is to see if elritercept works better to reduce the need for transfusions.
Baytown, TexasAges 18 years+ - NCT04493164RecruitingPhase 2
CPX-351 plus ivosidenib for IDH1-mutated leukemia or high-risk MDS
This trial tests CPX-351 together with ivosidenib in people with IDH1-mutated acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). It aims to improve disease control, especially in tumors with a specific genetic change called IDH1.
Houston, TexasAges 18 years+ - NCT05143996RecruitingPhase 1
First study drug for relapsed AML or MDS
This Phase 1 trial tests CLN-049 in adults whose acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) has come back or did not respond to treatment. The goal is to find out how well the drug can work and how safe it is in people with limited options.
Houston, TexasAges 18 years+ - NCT06548230RecruitingPhase 1/Phase 2
Nadunolimab plus azacitidine for MDS and AML
This trial tests a new combination of drugs (nadunolimab plus azacitidine, sometimes with venetoclax) for patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) that has not been treated much or has come back. The goal is to see if this combination can control the disease better.
Houston, TexasAges 18 years+ - NCT06501196RecruitingPhase 1
Study of BH-30236 for leukemia and high-risk MDS
This trial tests an experimental drug, BH-30236, for people with acute myeloid leukemia (AML) or a high-risk form of myelodysplastic syndrome (MDS) whose cancer has come back or stopped responding to treatment. It aims to see if the drug can help control the disease.
Houston, TexasAges 18 years+ - NCT03113643RecruitingPhase 1
SL-401 with standard drugs for hard-to-treat blood cancers
This Phase 1 study tests SL-401, given with azacitidine and sometimes venetoclax, to treat acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or blastic plasmacytoid dendritic cell neoplasm (BPDCN). It aims to find a safe dose and see whether the combination can improve blood cancer control.
Houston, TexasAges 18 years+ - NCT06247787RecruitingPhase 1
Imetelstat plus chemo for relapsed leukemia in kids
This trial tests a new drug called imetelstat combined with two chemotherapy drugs (fludarabine and cytarabine) for children and teens with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or juvenile myelomonocytic leukemia (JMML) that has come back or not responded to treatment. The goal is to find the safest dose of imetelstat and see if it helps control the cancer.
Houston, TexasAges 1–18 - NCT05320198RecruitingPhase 1/Phase 2
Testing DISC-0974 for anemia in myelofibrosis or MDS
This trial tests an investigational drug called DISC-0974 for people with myelofibrosis or certain types of MDS who have low red blood cell counts (anemia). The goal is to see if this treatment can help improve anemia and reduce the need for blood transfusions.
Houston, TexasAges 18 years+ - NCT05092451RecruitingPhase 1/Phase 2
CD70-targeting NK cell therapy for blood cancer relapse
This study tests an immune therapy made from cord blood “NK cells” that are engineered to attack cells with a marker called CD70. It’s given after chemotherapy that reduces your blood and immune system, aiming to treat relapse or refractory (not responding) blood cancers.
Houston, TexasAges 12–80 - NCT04256317RecruitingPhase 2/Phase 3
Azacitidine pills with or without venetoclax for certain blood cancers
This study tests whether a pill form of azacitidine (ASTX030) helps people with myelodysplastic syndromes (MDS), CMML, or AML. Some groups may also receive venetoclax; the goal is better blood cancer control for people who aren’t good candidates for intensive chemotherapy.
Dallas, TexasAges 18 years+ - NCT06834282RecruitingPhase 1
A study of CER-1236 for certain blood cancers
This trial tests an experimental cell therapy called CER-1236 for people with acute myeloid leukemia, myelodysplastic syndrome, or myelofibrosis. It aims to see if it can help treat these cancers.
Houston, TexasAges 18–85 - NCT05564390RecruitingPhase 2
MyeloMATCH screening to match you to AML or MDS treatment
This study screens people with newly suspected acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) to see which treatment approach fits best—either a specific study treatment or standard care. It may help by directing you to the right option and by sharing your blood/bone marrow samples for research.
Houston, TexasAges 18 years+ - NCT04093570Enrolling by invitationPhase 2
Extension study for people continuing ASTX727 from a prior trial
This study checks whether continuing ASTX727 for people who already benefited from it in an earlier Taiho study is safe and effective. It may be an option if you stayed on ASTX727 at the end of your parent study and your doctor felt it was helping you.
Dallas, TexasAges 18 years+ - NCT04227847RecruitingPhase 1
Study of a CD70-targeting drug for blood cancer
This Phase 1 study tests the safety of SEA-CD70, a drug that targets CD70, in people with certain blood cancers like MDS and AML. It may help doctors learn whether this approach can be used safely for patients whose disease has come back or not responded to standard treatments.
Dallas, TexasAges 18 years+ - NCT03214562RecruitingPhase 1/Phase 2
Venetoclax plus chemotherapy for acute leukemia
This trial studies how well venetoclax combined with chemotherapy treats newly diagnosed or returning (relapsed) or hard-to-treat (refractory) acute myeloid leukemia (AML). It’s mainly for people who can’t use standard AML therapy well, or whose disease came back.
Houston, TexasAges 18 years+ - NCT03452774Recruiting
AI matches your cancer tests to possible treatment trials
This trial uses an AI system to help match people with certain cancer types and specific tumor test results (like gene or protein markers) to relevant clinical trials. It may help you and your doctor find studies that fit your cancer biology faster.
Dallas, TexasAges Any age - NCT03471260RecruitingPhase 1/Phase 2
Ivosidenib and venetoclax for IDH1-mutated leukemia or MDS
This Phase 1/2 study tests whether the medicines ivosidenib and venetoclax (with or without azacitidine) can help people with certain “IDH1-mutated” blood cancers like AML or high-risk MDS. It’s meant for patients whose disease has come back, doesn’t respond, or who can’t safely get standard chemotherapy.
Houston, TexasAges 18 years+ - NCT03589729RecruitingPhase 2
Dexrazoxane to help protect the heart during blood-cancer chemo
This Phase 2 study tests dexrazoxane, a heart-protecting medicine, to reduce heart side effects from chemotherapy in people with certain blood cancers. If you qualify, you would receive dexrazoxane along with chemotherapy, and the team will monitor your heart function closely.
Houston, TexasAges 12 years+ - NCT03683433RecruitingPhase 2
Enasidenib plus azacitidine for IDH2-mutated AML
This trial studies the combination of enasidenib and azacitidine in people with acute myeloid leukemia (AML) that has an IDH2 gene mutation. It may help control the leukemia when prior treatments didn’t work or the disease came back.
Houston, TexasAges 18 years+ - NCT03850574RecruitingPhase 1/Phase 2
Tuspetinib for relapsed or hard-to-treat AML
This early-phase study tests tuspetinib in people with AML that has come back or did not respond to treatment. The goal is to learn whether it is safe and tolerable, how the drug behaves in the body, and whether it shows signs of benefit.
Huston, TexasAges 18 years+ - NCT04064060RecruitingPhase 3
Long-term safety follow-up for luspatercept study participants
This trial studies the long-term safety of luspatercept (ACE-536) in people who already took part in an earlier luspatercept study. It mainly helps doctors better understand ongoing side effects and overall safety over time.
Houston, TexasAges 18 years+
Myelodysplastic Syndromes trials by city in Texas
Where these studies are running in Texas
Institutions with a site for the recruiting myelodysplastic syndromes studies listed above.
- The University of Texas MD Anderson Cancer Center · 20 studies
- University of Texas Southwestern Medical Center · 3 studies
- Baylor College of Medicine · 2 studies
- Baylor Scott & White Research Institute · 2 studies
- Baylor University Medical Center · 2 studies
- Ben Taub General Hospital
- GI Alliance
- Lumi Research
What taking part in a myelodysplastic syndromes study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Myelodysplastic Syndromes trials in other states
Common questions
- Are there myelodysplastic syndromes clinical trials in Texas?
- Yes. We're currently tracking 68 recruiting myelodysplastic syndromes studies with a site in Texas, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a myelodysplastic syndromes study in Texas?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Texas to take part?
- Not necessarily. These studies have a site in Texas, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a myelodysplastic syndromes trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New myelodysplastic syndromes studies open in Texas regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.